Technical Analysis for BLCM - Bellicum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.14 3.64% 0.04
BLCM closed up 3.64 percent on Friday, September 20, 2019, on 1.11 times normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical BLCM trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 9.62%
Fell Below 20 DMA Bearish -0.44%
Wide Bands Range Expansion -0.44%
Wide Bands Range Expansion -5.00%
Narrow Range Bar Range Contraction -4.20%
NR7 Range Contraction -4.20%
Wide Bands Range Expansion -4.20%
50 DMA Resistance Bearish -5.00%
Expansion Pivot Sell Setup Bearish Swing Setup -5.00%
Outside Day Range Expansion -5.00%

Older signals for BLCM ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of various forms of cancer. Its lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Its preclinical product candidates include BPX-401, a chimeric antigen receptor (CAR-T) product candidate for the treatment of hematological cancers that express the CD19 antigen; BPX-601, a CAR-T product candidate for treating solid tumors overexpressing the prostate stem cell antigen; and BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Medicine Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatments Prostate Cancer Virotherapy Vaccination Melanoma Cell Therapy Immunotherapies Transplantation Kite Pharma Cancer Vaccine Hematological Cancers Chimeric Antigen Receptor Treatment Of Hematological Cancers Treatment Of Various Forms Of Cancer
Is BLCM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 6.64
52 Week Low 0.78
Average Volume 769,586
200-Day Moving Average 2.5757
50-Day Moving Average 1.2719
20-Day Moving Average 1.1716
10-Day Moving Average 1.1845
Average True Range 0.1147
ADX 19.54
+DI 18.1445
-DI 21.7372
Chandelier Exit (Long, 3 ATRs ) 1.0559
Chandelier Exit (Short, 3 ATRs ) 1.1241
Upper Bollinger Band 1.3257
Lower Bollinger Band 1.0175
Percent B (%b) 0.4
BandWidth 26.305906
MACD Line -0.0315
MACD Signal Line -0.0344
MACD Histogram 0.0029
Fundamentals Value
Market Cap 37.88 Million
Num Shares 33.2 Million
EPS -2.94
Price-to-Earnings (P/E) Ratio -0.39
Price-to-Sales 975.18
Price-to-Book 2.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.23
Resistance 3 (R3) 1.22 1.19 1.22
Resistance 2 (R2) 1.19 1.16 1.19 1.21
Resistance 1 (R1) 1.16 1.15 1.18 1.17 1.20
Pivot Point 1.13 1.13 1.13 1.13 1.13
Support 1 (S1) 1.10 1.10 1.12 1.11 1.08
Support 2 (S2) 1.07 1.09 1.07 1.07
Support 3 (S3) 1.04 1.07 1.07
Support 4 (S4) 1.05